Your browser doesn't support javascript.
loading
Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR.
Pothin, Elodie; Lesuisse, Dominique; Lafaye, Pierre.
Afiliación
  • Pothin E; Antibody Engineering Platform, Structural Biology and Chemistry Department, Institut Pasteur, 75015 Paris, France.
  • Lesuisse D; Tissue Barriers, Rare and Neurological Diseases TA Department, Sanofi, 91161 Chilly-Mazarin, France.
  • Lafaye P; Tissue Barriers, Rare and Neurological Diseases TA Department, Sanofi, 91161 Chilly-Mazarin, France.
Pharmaceutics ; 12(10)2020 Sep 30.
Article en En | MEDLINE | ID: mdl-33007904
Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza